Florey researchers are testing a blood test for Alzheimer’s disease
Researchers at The Florey Institute have evaluated a new blood test for Alzheimer’s disease, demonstrating its reliability in detecting the presence and severity of the condition.
This development brings the medical community closer to an earlier and more accurate diagnostic tool.
Plasma pTau217 blood tests, which were previously established as accurate in identifying Alzheimer’s disease, are not yet available for clinical use.
However, a study published in eBioMedicine has evaluated the performance of this assay using the Lumipulse-G platform, a device that is already in use worldwide for other clinical trials but has not yet been approved for pTau217 testing.
Japanese diagnostic company Fujirebio has Lumipulse-G Plasma pTau217 and expects it to be the first blood test available in the U.S. to diagnose Alzheimer’s disease.
Professor Christopher Rowe of The Florey is senior academic author and clinical lead for the Dementia Mission.
Find the most comprehensive Company Information on the market, powered by GlobalData. Save hours of research. Find competitive positions.
Company profile – free sample
Your download email will arrive shortly
We are confident in the exceptional quality of our Company Files. However, we want you to make the best decision for your business, so we are offering a free sample that you can download by submitting the form below.
By GlobalData
Rowe said the test was “highly reliable” when used with the Lumipulse device.
He said: “We compared the results of the patients’ blood test with the PET scan and found that plasma pTau217 not only confirms whether a person has Alzheimer’s disease, but whether they are in the middle or advanced stage. more advanced than the former.”
The data came from patient samples and PET scans provided to the Australian Dementia Network (ADNeT) and the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing.
With these findings, patients are one step closer to receiving a low-cost test that can accurately diagnose Alzheimer’s disease early, which is critical as treatments for the early stages of the disease continue to develop.
The first author, Azadeh Feizpour, said: “As a new generation of drugs is emerging to treat Alzheimer’s disease, recognizing the stage of the disease will be important.”
Sign up for our daily newsletter!
Promote your business with our industry leading data.
#Florey #researchers #testing #blood #test #Alzheimers #disease